BUZZ-Moderna falls as Morgan Stanley cuts PT
** Shares of vaccine maker Moderna MRNA.O fall 1.2% to $34.04 premarket
** Brokerage Morgan Stanley lowers PT on MRNA to $38 from $70; maintains "equal-weight" rating
** New PT represents a 10.3% upside to the stock's last close
** On Monday, MRNA cut its 2025 sales forecast by $1 bln, hurt by slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines
** Brokerage says investors will focus on whether MRNA can achieve its 2028 "breakeven target" or if it may need to raise more equity
** Brokerage notes MRNA's pipeline execution, with INT program with Merck MRK.N being a "significant opportunity" and Cytomegalovirus (CMV) vaccine a "near-term focus"
** MRNA fell 63.1% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Related Articles
TSMC Delivers Record High Q4 2024 Profit: Shares Rise 4%
TradingKey - For semiconductor companies, there’s a lot of expectation heading into the latest earnings season as the Artificial Intelligence (AI) hype continues.
Can Earnings Season Be the Catalyst for U.S. Stocks?
TradingKey - Fears of persistent inflation, driven by strong employment data and Trump’s potential policies, have raised concerns that the Federal Reserve may scale back planned rate cuts. Combined with worries over high valuations and a potential stock market bubble, these factors have increased se
What Impact Will California Wildfires Have on The Stock Market?
TradingKey - Right now in the US, there are ferocious wildfires that are destroying acres of both land and homes in California. Being spread by strong winds, the fires are also heading towards major urban centres, like Los Angeles.
